

Coromandel International

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	CRIN IN
Equity Shares (m)	295
M.Cap.(INRb)/(USDb)	653.6 / 7.1
52-Week Range (INR)	2720 / 1588
1, 6, 12 Rel. Per (%)	2/-17/17
12M Avg Val (INR M)	1338

Financials & Valuations (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	314.7	349.8	374.6
EBITDA	32.6	41.7	45.9
PAT	21.2	29.2	33.0
EBITDA (%)	10.4	11.9	12.3
EPS (INR)	72.0	99.1	112.0
EPS Gr. (%)	17.5	37.6	13.1
BV/Sh. (INR)	434.6	519.7	617.7

Ratios

Net D/E	-0.2	-0.3	-0.4
RoE (%)	17.7	20.8	19.7
RoCE (%)	19.4	21.7	20.6
Payout (%)	19.4	14.1	12.5

Valuations

P/E (x)	30.9	22.4	19.8
EV/EBITDA (x)	19.4	14.4	12.6
Div Yield (%)	0.6	0.6	0.6
FCF Yield (%)	-0.9	4.6	4.0

Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	56.9	56.9	57.0
DII	16.7	15.9	21.0
FII	13.9	14.6	8.3
Others	12.6	12.7	13.7

CMP: INR2,216

TP: INR2,800 (+26%)

Buy

Operational efficiencies cushion weather-related disruptions

Operating performance misses estimates

- Coromandel International (CRIN) continued to deliver healthy operating performance in 3QFY26 (EBITDA up 11% YoY), supported by continued traction in crop protection (EBIT up 47% YoY).
- We expect sulphur prices to normalize, while benefits from backward integration are likely to cushion fertilizer margins.
- Crop protection growth is expected to be led by sustained demand for key fungicide molecules (including Mancozeb), continued new product launches, and expansion in domestic formulations. Meanwhile, NACL integration is expected to support medium-term growth and margin expansion from FY27 onwards.
- We cut our FY26 earnings estimate by 7% due to lower-than-expected earnings in 3QFY26, while maintaining our estimates for FY27 and FY28. We value the company at ~25x FY28E EPS to arrive at a **TP of INR2,800**. Reiterate **BUY**.

Higher trading volumes lead to a decline in profitability

- CRIN reported revenue of INR87.8b (est. INR83.1b) in 3QFY26, up 27% YoY. Total manufacturing fertilizer volumes (NPK+DAP) declined marginally by 2% YoY to 892kmt, and total phosphate fertilizer manufacturing volumes (including SSP) rose marginally 1% YoY to 1.1mmt. Overall phosphatic volumes (NPK + DAP) declined marginally by 2% to 1.12mmt.
- Nutrient & other allied business revenue rose 22% YoY to INR77.6b, while crop protection business revenue grew 73% YoY to INR11b. Standalone crop protection (i.e. ex NACL) business grew 24% to INR7.9b.
- EBITDA grew 11% YoY to INR8b (est. in line). According to our calculations, manufacturing EBITDA/mt (including SSP) stood at INR4,571 (flat YoY), while EBITDA/mt for phosphate fertilizers (DAP and NPK) stood at INR5,353 (flat YoY).
- EBIT margin for the nutrient & other allied business contracted 200bp YoY to 7.8% due to a sharp increase in key raw material prices, while EBIT margin for the crop protection business contracted 210bp YoY to 12.2% (due to the consolidation of NACL). However, standalone EBIT margins expanded 570bp YoY to 20.2% due to a favorable product mix, improved realizations in key fungicide molecules, and operating leverage.
- Adjusted PAT stood at INR5.1b (est. INR6b), declining marginally by 1% YoY.
- CRIN's 9MFY26 revenue/EBITDA/Adj. PAT grew 33%/24%/22% to INR255b/INR27.3b/INR18.2b. Total manufactured fertilizer volume (NPK + DAP) grew 2% YoY to ~2.9mmt, and total phosphate fertilizer manufacturing volumes (including SSP) grew 3% YoY to 3.5mmt.

Highlights from the management commentary

- **Backward Integration and capex:** CRIN's sulphuric acid and phosphoric acid backward integration projects at Kakinada are progressing as planned, with a combined capex of ~INR2b and expected annual value addition of ~INR4b. In addition, the granulation expansion project is scheduled for commissioning in 3QFY27, with management guiding for full utilization from inception.
- **EBITDA/MT improvement:** CRIN indicated that normalized EBITDA of ~INR5,500/ton is expected to improve to ~INR6,500/ton on an annualized basis post backward integration, driven by captive acid sourcing and integrated power benefits.
- **Subsidy:** During the quarter, CRIN received INR25.71b/INR72.08b in subsidy claims for 3Q/1HFY26, compared to INR20.36b in 3QFY25. As of Dec'25, outstanding subsidies stood at ~INR37.85b compared to INR20.95b as of Dec'24.
- **Crop protection:** Crop protection revenue grew ~30% YoY in exports and ~36% YoY in domestic B2B, driven by volume growth and higher realizations in key technical molecules, while domestic B2C formulations saw low single-digit growth due to adverse weather. New products contributed ~25% of YTD revenue, and channel expansion added ~1,000 dealers, strengthening market reach and portfolio depth.

Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY27, supported by favorable market dynamics, increasing shift toward NPK fertilizers for balanced nutrition, and strong growth in crop protection led by synergy benefits of the NACL consolidation.
- CRIN's medium-term outlook remains strong, backed by: 1) expansion into new geographies, 2) development of new molecules across fertilizers and crop protection segments, 3) backward integration for the fertilizer business, 4) acquisition of NACL, and 5) the scale-up of BMCC.
- We cut our FY26 earnings estimate by 7% due to lower-than-expected earnings in 3QFY26 while maintaining our estimates % for FY26/FY27/FY28. We value the company at ~25x FY28E EPS to arrive at a **TP of INR2,800. Reiterate BUY.**

Quarterly Performance										(INR m)		
Y/E March	FY25				FY26				FY25	FY26E	FY26	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
Consolidated	47,288	74,328	69,352	49,884	70,423	96,541	87,795	59,975	2,40,852	3,14,734	83,128	6
Net Sales	47,288	74,328	69,352	49,884	70,423	96,541	87,795	59,975	2,40,852	3,14,734	83,128	6
YoY Change (%)	-16.9	6.4	26.9	27.5	48.9	29.9	26.6	20.2	9.2	30.7	19.9	
Total Expenditure	42,231	64,581	62,134	45,624	62,602	85,076	79,798	54,678	2,14,569	2,82,154	74,730	
EBITDA	5,058	9,748	7,218	4,260	7,821	11,465	7,996	5,297	26,283	32,580	8,399	-5
Margins (%)	10.7	13.1	10.4	8.5	11.1	11.9	9.1	8.8	10.9	10.4	10.1	
Depreciation	653	690	708	854	1,206	1,018	1,466	1,490	2,904	5,179	1,215	
Interest	574	661	731	659	680	1,018	835	750	2,624	3,283	550	
Other Income	541	650	1,137	1,260	837	1,165	832	1,200	3,587	4,034	1,307	
PBT before EO expense	4,372	9,047	6,916	4,007	6,773	10,595	6,528	4,257	24,342	28,152	7,941	
Extra-Ord expense	0	0	0	-3,468	0	0	0	0	-3,468	0	0	
PBT	4,372	9,047	6,916	7,475	6,773	10,595	6,528	4,257	27,810	28,152	7,941	
Tax	1,125	2,328	1,752	1,524	1,757	2,660	1,643	1,075	6,728	7,135	1,999	
Rate (%)	25.7	25.7	25.3	20.4	25.9	25.1	25.2	25.3	24.2	25.3	25.2	
Minority Interest & P/L of Asso. Cos.	137	79	46	154	-34	-119	-174	152	417	-175	-36	
Reported PAT	3,110	6,641	5,118	5,797	5,050	8,053	5,059	3,031	20,665	21,193	5,978	
Adj PAT	3,110	6,641	5,118	3,036	5,050	8,053	5,059	3,031	18,036	21,193	5,978	-15
YoY Change (%)	-37.1	-12.3	121.6	89.4	62.4	21.3	-1.2	-0.2	9.8	17.5	16.8	
Margins (%)	6.6	8.9	7.4	6.1	7.2	8.3	5.8	5.1	7.5	6.7	7.2	

Key Performance Indicators

Y/E March Consolidated	FY25			FY26			FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q		
Volume Growth (%)	-3.4	24.6	14.6	23.6	28.2	12.7	29.2	14.9
Manufacturing (%)	3.3	6.3	7.6	22.8	11.8	-1.6	0.5	8.7
Trading (%)	-22.4	116.1	28.3	24.8	89.9	47.8	76.3	30.6
Mfg EBITDA/MT (INR)	4,261	5,435	4,609	4,177	5,118	6,340	4,571	4,150
Cost Break-up								
RM Cost (% of sales)	73.6	74.9	76.4	70.3	74.4	76.3	76.9	74.1
Staff Cost (% of sales)	3.9	2.5	3.0	4.2	3.2	2.7	3.3	3.3
Freight Cost (% of sales)	6.0	5.0	5.4	6.4	5.4	4.1	5.1	5.6
Other Cost (% of sales)	5.8	4.5	4.9	10.6	5.9	5.0	5.7	6.1
Gross Margins (%)	26.4	25.1	23.6	29.7	25.6	23.7	23.1	25.9
EBITDA Margins (%)	10.7	13.1	10.4	8.5	11.1	11.9	9.1	10.9
EBIT Margins (%)	9.3	12.2	9.4	6.8	9.4	10.8	7.4	9.7

Key exhibits

Exhibit 1: Revenue trend




Exhibit 2: EBITDA trend




Exhibit 3: Adjusted PAT trend




Exhibit 4: Trend in outstanding subsidy




Exhibit 5: Price trend in phosphoric acid




Exhibit 6: Segmental revenue and EBIT trends

INR m	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
Segment revenue										
Nutrient and Other Allied	63,017	49,027	33,702	42,137	67,503	63,674	43,210	63,517	86,609	77,618
YoY growth (%)	-33%	-36%	-31%	-19%	7%	30%	28%	51%	28%	22%
Crop Protection	7,301	6,154	5,644	5,516	7,511	6,357	6,987	7,249	10,689	10,983
YoY growth (%)	3%	-6%	-8%	1%	3%	3%	24%	31%	42%	73%
Less: Inter-segment	437	540	219	364	686	678	313	343	756	806
Total	69,881	54,642	39,127	47,288	74,328	69,352	49,884	70,423	96,541	87,795
Segment EBIT										
Nutrient and Other Allied	9,913	2,516	2,515	4,317	8,507	6,261	2,973	6,295	9,834	6,066
Margin (%)	15.7%	5.1%	7.5%	10.2%	12.6%	9.8%	6.9%	9.9%	11.4%	7.8%
Crop Protection	871	846	631	629	1,083	910	1,011	1,112	1,452	1,342
Margin (%)	11.9%	13.7%	11.2%	11.4%	14.4%	14.3%	14.5%	15.3%	13.6%	12.2%
Unallocated expenses	737	419	1,046	540	532	661	1,088	791	838	877
Total	10,048	2,943	2,100	4,405	9,058	6,510	2,897	6,615	10,448	6,531

Source: Company, MOFSL

Exhibit 7: Volume trend

Quarterly volume trend ('000MT)	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
Manufactured									
NPK	817	506	726	1,086	912	607	893	1,073	892
Growth (%)	-8%	-5%	2%	9%	12%	20%	23%	-1%	-2%
DAP	59	33	85	0	0	0	0	0	0
Growth (%)	111%	371%	93%						
SSP	143	119	157	231	184	201	189	223	210
Growth (%)	-34%	-37%	-12%	9%	29%	69%	20%	-3%	14%
Total Manufacturing	1,019	658	968	1,317	1,096	808	1,082	1,296	1,102
Growth (%)	-10%	-10%	3%	6%	8%	23%	12%	-2%	1%
Traded									
MOP	22	12	7	29	20	13	6	14	23
Growth (%)	1000%	1100%	-36%	-22%	-9%	8%	-14%	-52%	15%
DAP Traded	62	51	27	181	227	97	193	236	199
Growth (%)	-54%	-41%	-72%	37%	266%	90%	615%	30%	-12%
NPK Traded	0	0	0	43	0	0	14	97	28
Urea	436	372	223	283	420	433	275	445	926
Growth (%)	9%	-31%	0%	258%	-4%	16%	23%	57%	120%
Total Trading	520	435	257	536	667	543	488	792	1,176
Growth (%)	-3%	-31%	-22%	116%	28%	25%	90%	48%	76%
Total Trading + Mfg.	1,539	1,093	1,225	1,853	1,763	1,351	1,570	2,088	2,278
Growth (%)	-8%	-20%	-3%	25%	15%	24%	28%	13%	29%
Total NPK (mfg. + trading)	817	506	726	1,129	912	607	907	1,170	920
Growth (%)	-8%	-5%	2%	14%	12%	20%	25%	4%	1%
Total DAP (mfg. + trading)	121	84	112	181	227	97	193	236	199
Growth (%)	-26%	-11%	-21%	10%	88%	15%	72%	30%	-12%
Total phosphatic fertilizer	938	590	838	1,310	1,139	704	1,100	1,406	1,119
Growth (%)	-11%	-6%	-2%	13%	21%	19%	31%	7%	-2%

Source: Company, MOFSL



Highlights from the management commentary

Industry scenario

- The weather disruptions from delayed southwest monsoon hurt kharif demand in 3Q, while normal northeast monsoon rainfall and reservoir levels at 125% of LTA supported ~3% YoY growth in rabi sowing.
- Fertilizer industry consumption declined ~7% YoY in 3Q due to extended monsoon, even as industry primary sales grew ~15% in 9MFY26, aided by inventory replenishment and higher imports.
- Structural shift toward NPK fertilizers continues, with NPK now accounting for ~50% of phosphatic fertilizer consumption, supporting demand for differentiated grades.
- Raw material costs remained volatile, with sharp increases in sulphur, ammonia, and phosphoric acid prices driven by global supply disruptions and China-led demand, partially offset by softer rock phosphate prices.
- Regulatory developments such as the Draft Pesticides Management Bill and Draft Seeds Bill are expected to formalize the sector, improve traceability, and enhance long-term industry stability.
- Medium-term industry outlook remains stable despite near-term volatility, supported by rabi recovery, policy continuity, digital subsidy processes, and export opportunities under the India–EU FTA.
- Phosphoric acid prices rose from ~USD1,050/ton to ~USD1,290/ton YoY, while rock phosphate prices softened, partially offsetting cost pressures.

Outlook

- Management expects fertilizer demand to recover in the coming quarters, supported by normal rabi sowing, adequate reservoir levels, and continued government subsidy support.
- Management expects the current sulphur price spike to be temporary, with normalization likely by 1QFY27.
- CRIN's volumes and market share are likely to benefit from full capacity utilization, backward integration projects, and differentiated NPK and specialty fertilizer offerings.
- Crop protection business is positioned for growth, driven by new product launches, B2C expansion, and sustained export demand, particularly for key molecules like Mancozeb.
- Medium-term growth remains strong across fertilizers, specialty nutrients, nano products, and digital initiatives, with management targeting 20-25% YoY growth in domestic formulations and operational synergies from NACL integration.

Subsidy

- Subsidy collections remained timely and strong, with INR25.71b collected in 3Q versus INR20.36b last year; for the nine-month period, collections were INR72.08b compared to INR58.91b in the previous year.
- Subsidy outstanding as of Dec'25 stood at INR37.85b versus INR20.95b last year; an additional ~INR13.b was collected in January, covering sales up to the last week of December, indicating continued robustness in collections.
- Government support remains strong, with INR180b supplementary subsidy released in 3Q, FY26 subsidy outgo expected at ~INR1.86t, and FY27 allocations viewed as adequate with scope for additional grants.

- Fertilizer subsidy remains the backbone of the industry, contributing ~82% of revenues and ~62% of EBITDA, providing earnings visibility despite raw material volatility.
- FY27 subsidy allocation of INR1.17t for urea and INR540b for phosphatic fertilizers under NBS is viewed as adequate, with precedent of additional grants if costs rise.

Fertilizer Business Performance

- The 3Q was challenging due to higher raw material costs, INR depreciation, and weak consumption, but Coromandel delivered a resilient performance through competitive sourcing, operational efficiency, and full capacity utilization.
- The company achieved its highest-ever quarterly fertilizer production of ~990k tons, up 18% YoY, with phosphoric acid production also increasing YoY.
- Primary fertilizer sales for 3Q stood at ~1.12m tons, broadly flat YoY, with moderated sales in Andhra Pradesh and Telangana offset by strong performance in Maharashtra, Karnataka, Tamil Nadu, and northern markets.
- Consumption-based market share declined from 15% to 14% in Q3 due to regional crop issues, while the share of differentiated grades improved from 33% to 36%.
- The selective price hikes of 3-4% were implemented to partially offset cost inflation, and the SSP business remained strong, with differentiated products contributing ~47% of SSP volumes.

Crop protection business

- Revenues from export increased ~30% YoY, driven by volume growth and higher realizations in key technical molecules.
- Domestic B2B institutional sales grew ~36% YoY, while domestic B2C formulation sales were muted due to adverse weather, rising only in low single digits.
- New products contributed ~25% of year-to-date revenues, reflecting successful innovation and portfolio expansion.
- Channel expansion added approximately 1,000 dealers during the year, strengthening market reach.

Specialty Nutrients, Nano & New Initiatives

- The specialty nutrient business, including water-soluble fertilizers and organics, achieved record 3Q volumes, with strong growth in micronutrients and organic categories.
- Four new products were launched during the quarter, and the MEP water-soluble fertilizer plant at Vizag commenced operations.
- Nano products grew ~68% YoY, with CRIN emerging as the market leader in nano-DAP, which gained strong traction in horticulture crops.
- The company's global trials are underway, and the export opportunities are expected once registrations are completed.
- The retail network expanded to 2,113 stores, strengthening market presence and customer access.

Backward Integration & CAPEX

- Sulphuric acid and phosphoric acid backward integration projects at Kakinada are on track for commissioning, with a combined CAPEX of ~INR2b.

- These projects are expected to generate an annual value addition of ~INR4b, supported by an integrated power generation capacity of ~24 MW.
- Management highlighted long-term EBITDA potential, with current normalized EBITDA at ~INR5,500/ton and post-integration potential of ~INR6,500/ton on an annualized basis.
- The granulation expansion project is targeted for commissioning in 3QFY27, with management expecting 100% utilization from day one.
- Overall, these initiatives aim to strengthen backward integration, operational efficiency, and long-term profitability.

Others

- Mancozeb remains central to Coromandel's export strategy, with structurally increased demand due to additional spray cycles in Brazil and farmer preference for cost-effective fungicides.
- Mancozeb's capacity expanded by ~20%, with a further 30% expansion planned; combination products are being developed, and Latin America registrations are underway. Its strategy includes a selective B2C presence overseas.
- NACL integration is progressing with improved liquidity and working capital discipline, standalone margins at ~19%, hedge constraints being addressed, and visible synergies across R&D, manufacturing, marketing, and registrations expected from 1QFY27.
- CRIN's Senegal rock phosphate mine meets ~20-25% of its requirements, exceeded initial production targets (~350k tons vs 300k tons) with plans to scale to ~500k tons annually, provides supply security and cost stability, and remains profitable standalone while vessel integration and recovery improvements continue.

Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY27, supported by favorable market dynamics, increasing shift toward NPK fertilizers for balanced nutrition, and strong growth in crop protection led by synergy benefits of the NACL consolidation.
- CRIN's medium-term outlook remains strong, backed by: 1) expansion into new geographies, 2) development of new molecules across fertilizers and crop protection segments, 3) backward integration for the fertilizer business, 4) acquisition of NACL, and 5) the scale-up of BMCC.
- We cut our FY26 earnings estimate by 7% due to lower than expected earnings in 3QFY26 while maintaining our estimates % for FY26/FY27/FY28. We value the company at ~25x FY28E EPS to arrive at a **TP of INR2,800. Reiterate BUY.**

Exhibit 8: Revisions to our estimates

Earnings Change (INR m)	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	3,09,776	3,45,452	3,70,895	3,14,734	3,49,830	3,74,628	2%	1%	1%
EBITDA	33,204	41,270	45,476	32,580	41,733	45,892	-2%	1%	1%
Adj. PAT	22,842	29,420	33,307	21,193	29,166	32,980	-7%	-1%	-1%

Source: MOFSL

Financials and valuations

Consolidated - Income Statement									(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Income from Operations	1,41,820	1,91,109	2,96,279	2,20,584	2,40,852	3,14,734	3,49,830	3,74,628	
Less: Excise Duty	0	0	0	0	0	0	0	0	0
Total Income from Operations	1,41,820	1,91,109	2,96,279	2,20,584	2,40,852	3,14,734	3,49,830	3,74,628	
Change (%)	8.0	34.8	55.0	(25.5)	9.2	30.7	11.2	7.1	
Total Expenditure	1,21,977	1,69,610	2,67,017	1,96,596	2,14,569	2,82,154	3,08,097	3,28,736	
EBITDA	19,843	21,499	29,262	23,988	26,283	32,580	41,733	45,892	
Margin (%)	14.0	11.2	9.9	10.9	10.9	10.4	11.9	12.3	
Depreciation	1,731	1,727	1,820	2,286	2,904	5,179	5,460	5,496	
EBIT	18,112	19,772	27,442	21,702	23,379	27,401	36,273	40,397	
Int. and Finance Charges	1,057	755	1,900	1,866	2,624	3,283	1,800	1,600	
Other Income	751	1,443	1,711	2,314	3,587	4,034	4,841	5,809	
PBT bef. EO Exp.	17,806	20,460	27,253	22,150	24,342	28,152	39,314	44,606	
EO Expense/(Income)	0	0	0	0	3,468	0	0	0	
PBT after EO Exp.	17,806	20,460	27,253	22,150	27,810	28,152	39,314	44,606	
Total Tax	4,568	5,213	6,879	5,478	6,728	7,135	9,895	11,227	
Tax Rate (%)	25.7	25.5	25.2	24.7	24.2	25.3	25.2	25.2	
Less: MI/Sh of profit/loss of JV & Ass.	-54	-37	245	250	417	-175	253	398	
Reported PAT	13,292	15,285	20,129	16,422	20,665	21,193	29,166	32,980	
Adjusted PAT	13,292	15,285	20,129	16,422	18,036	21,193	29,166	32,980	
Change (%)	24.8	15.0	31.7	-18.4	9.8	17.5	37.6	13.1	
Margin (%)	9.4	8.0	6.8	7.4	7.5	6.7	8.3	8.8	

Consolidated - Balance Sheet									(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Equity Share Capital	293	294	294	294	294	294	294	294	294
Total Reserves	51,213	63,289	78,784	93,905	1,10,584	1,27,655	1,52,699	1,81,558	
Net Worth	51,506	63,583	79,078	94,199	1,10,878	1,27,949	1,52,994	1,81,852	
Deferred Liabilities	576	660	591	827	837	837	837	837	
Total Loans	16	0	46	518	2,322	1,322	822	322	
Capital Employed	52,098	64,243	79,715	95,814	1,15,386	1,31,457	1,56,002	1,84,360	
Gross Block	36,849	39,337	42,245	46,769	51,506	70,080	75,531	79,281	
Less: Accum. Deprn.	16,698	18,424	20,244	22,529	25,433	30,612	36,072	41,568	
Net Fixed Assets	20,151	20,913	22,001	24,240	26,073	39,468	39,458	37,712	
Goodwill on Consolidation	3	3	3	2,849	2,849	6,702	6,702	6,702	
Capital WIP	898	1,412	3,993	2,355	3,525	2,951	2,500	3,750	
Current Investments	0	0	0	0	0	0	0	0	
Total Investments	2,138	2,435	2,867	8,538	10,308	10,308	10,308	10,308	
Curr. Assets, Loans&Adv.	65,765	88,085	1,13,484	1,20,534	1,46,418	1,56,046	1,89,616	2,24,649	
Inventory	26,009	36,632	44,165	46,125	47,699	56,049	62,298	66,715	
Account Receivables	5,544	2,649	5,893	13,935	12,291	14,659	15,335	16,422	
Govt Subsidies Receivable	5,897	2,941	23,779	13,772	16,536	21,557	23,961	25,659	
Cash and Bank Balance	7,221	17,533	14,178	28,586	35,383	24,978	53,517	78,903	
Loans and Advances	21,094	28,330	25,470	18,116	34,509	38,803	34,504	36,950	
Curr. Liability & Prov.	36,857	48,605	62,633	62,702	73,890	84,120	92,685	98,864	
Account Payables	29,222	39,135	53,138	53,606	60,300	71,029	77,248	82,362	
Other Current Liabilities	7,281	9,132	9,057	8,606	12,995	12,072	14,377	15,396	
Provisions	354	337	439	489	595	1,019	1,061	1,107	
Net Current Assets	28,908	39,481	50,851	57,832	72,529	71,926	96,930	1,25,785	
Appl. of Funds	52,098	64,243	79,715	95,814	1,15,386	1,31,457	1,56,002	1,84,360	

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)								
EPS	45.3	52.1	68.5	55.8	61.3	72.0	99.1	112.0
Cash EPS	51.2	58.0	74.7	63.5	71.1	89.6	117.6	130.7
BV/Share	175.5	216.6	269.0	320.0	376.6	434.6	519.7	617.7
DPS	12.0	12.0	12.0	12.0	14.0	14.0	14.0	14.0
Payout (%)	26.5	23.0	17.5	21.5	19.9	19.4	14.1	12.5
Valuation (x)								
P/E	49.0	42.7	32.5	39.8	36.3	30.9	22.4	19.8
Cash P/E	43.4	38.3	29.8	35.0	31.2	24.8	18.9	17.0
P/BV	12.7	10.3	8.3	6.9	5.9	5.1	4.3	3.6
EV/Sales	4.5	3.3	2.2	2.8	2.6	2.0	1.7	1.5
EV/EBITDA	32.5	29.5	21.8	26.1	23.7	19.4	14.4	12.6
Dividend Yield (%)	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6
FCF per share	121.3	60.6	1.4	29.0	69.0	-21.1	103.2	89.0
Return Ratios (%)								
RoE	28.1	26.6	28.2	19.0	17.6	17.7	20.8	19.7
RoCE	25.3	27.5	30.5	20.8	19.7	19.4	21.7	20.6
RoIC	27.4	34.8	40.4	28.4	28.9	25.7	29.7	33.4
Working Capital Ratios								
Fixed Asset Turnover (x)	4	5	7	5	5	4	5	5
Asset Turnover (x)	2.7	3.0	3.7	2.3	2.1	2.4	2.2	2.0
Inventory (Days)	67	70	54	76	72	65	65	65
Debtor (Days)	14	5	7	23	19	17	16	16
Govt Subs Receivable (days)	15	6	29	23	25	25	25	25
Creditor (Days)	110	100	83	119	123	110	110	110
Others (Days)								
Working Capital Turnover (Days)	56	42	45	48	56	54	45	46
Leverage Ratio (x)								
Current Ratio	1.8	1.8	1.8	1.9	2.0	1.9	2.0	2.3
Interest Cover Ratio	17	26	14	12	9	8	20	25
Debt/Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Consolidated - Cash Flow Statement

(**INRm**)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
NP/(Loss) Before Tax and EO Items	17,806	20,460	27,253	22,150	27,276	28,152	39,314	44,606
Depreciation	1,731	1,727	1,820	2,286	2,904	5,179	5,460	5,496
Interest & Finance Charges	1,057	755	189	-448	258	-751	-3,041	-4,209
Direct Taxes Paid	-4,568	-4,834	-7,038	-5,478	-7,187	-7,135	-9,895	-11,227
(Inc)/Dec in WC	25,476	3,716	-16,520	7,427	4,520	-9,802	3,534	-3,468
CF from Operations	41,502	21,824	5,703	25,936	27,771	15,643	35,372	31,197
Others	0	-1,044	207	-11,659	-3,133	0	0	0
CF from Operating incl EO	41,502	20,781	5,910	14,277	24,638	15,643	35,372	31,197
(inc)/dec in FA	-5,926	-3,002	-5,489	-5,732	-4,335	-21,853	-5,000	-5,000
Free Cash Flow	35,576	17,779	421	8,545	20,303	-6,210	30,372	26,197
(Pur)/Sale of Investments	-25	-297	-432	-5,671	-45,620	0	0	0
Others	-6,622	-12,921	12,312	-1,940	23,578	4,034	4,841	5,809
CF from Investments	-12,572	-16,220	6,390	-13,343	-26,377	-17,819	-159	809
Issue of Shares	0	0	1	0	168	0	0	0
Inc/(Dec) in Debt	-16,235	-16	46	472	-516	-1,000	-500	-500
Interest Paid	-1,057	-755	-1,900	-1,866	-2,150	-3,283	-1,800	-1,600
Dividend Paid	-3,521	-3,522	-3,528	-3,533	-3,528	-4,122	-4,122	-4,122
Others	-1,679	10,044	-10,273	18,400	14,563	175	-253	-398
CF from Fin. Activity	-22,491	5,751	-15,655	13,474	8,537	-8,229	-6,674	-6,620
Inc/Dec of Cash	6,438	10,312	-3,355	14,408	6,798	-10,405	28,539	25,386
Add: Beginning Balance	783	7,221	17,533	14,178	28,586	35,384	24,978	53,517
Closing Balance	7,221	17,533	14,178	28,586	35,384	24,978	53,517	78,903

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .. 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.